Teachers Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Teachers Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$2.43M	Buy	108,875 +3,465	+3%	+$81.6K	﹤0.01%	1863
2018 Q4	$2.52M	Buy	105,410 +2,332	+2%	+$60.3K	﹤0.01%	1711
2018 Q3	$2.81M	Buy	103,078 +20,751	+25%	+$587K	﹤0.01%	1782
2018 Q2	$2.21M	Buy	82,327 +18,707	+29%	+$573K	﹤0.01%	1900
2018 Q1	$2.02M	Hold	63,620	–	–	﹤0.01%	1823
2017 Q4	$2.41M	Sell	63,620 -875	-1%	-$28.2K	﹤0.01%	1732
2017 Q3	$1.6M	Buy	64,495 +1,458	+2%	+$31.4K	﹤0.01%	1968
2017 Q2	$1.3M	Buy	63,037 +18,688	+42%	+$357K	﹤0.01%	2075
2017 Q1	$964K	Buy	44,349 +1,120	+3%	+$23K	﹤0.01%	2202
2016 Q4	$884K	Buy	43,229 +1,025	+2%	+$21K	﹤0.01%	2243
2016 Q3	$633K	Hold	42,204	–	–	﹤0.01%	2341
2016 Q2	$457K	Buy	42,204 +25,433	+152%	+$346K	﹤0.01%	2470
2016 Q1	$227K	Hold	16,771	–	–	﹤0.01%	2753
2015 Q4	$309K	Buy	16,771 +5,477	+48%	+$101K	﹤0.01%	2693
2015 Q3	$286K	Buy	+11,294	New	+$264K	﹤0.01%	2717

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Teachers Advisors's AIMT Position: Q1 2019 in Review

Teachers Advisors increased its Aimmune Therapeutics (AIMT) stake by 3.3% in Q1 2019, buying an estimated $81.6K and bringing the position to 108,875 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

Teachers Advisors first reported a position in AIMT in Q3 2015 and has held it in 15 quarters since. The position peaked at $2.81M in Q3 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

Teachers Advisors held 108,875 shares of Aimmune Therapeutics worth $2.43M as of Q1 2019.
Teachers Advisors bought 3,465 Aimmune Therapeutics shares in Q1 2019, an estimated $81.6K.
Aimmune Therapeutics made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #1863 holding.
Teachers Advisors first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 15 quarters since.
Teachers Advisors's Aimmune Therapeutics position peaked at $2.81M in Q3 2018.
125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.